Ann: ResApp Presentation at ASX Spotlight Investor Conference, page-45

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 45 Last

Share
Profile

Follow
mumstheword

2,526 Posts.

272

01/06/17

16:36

Post #: 25045782
Share

Originally posted by green8 ↑

I attended the asx spotlight presentation in Singapore and watched TK present well to a room that was packed with Asian investors.

In comparison with other presentations during the day the Resapp story is to me the most exciting, and has the largest commercial potential in a relatively short time frame.

TK & BL were busy before and after the presentation meeting with Asian investors in one on one meetings. Apparently, he also presented to a room of Singapore hedge funds the day before.

TK was excited in relation to the USA testing with the fact all our “buckets” are now full / “overflowing” which will enable parallel submission to FDA for all the illnesses mentioned in the recent announcement, not just pneumonia. Once the administration is done over the next few weeks, our algorithm will then run through the audio files and we will have our results.

TK knows the importance of the usa results and he & BL have 70 million+ reasons to work around the clock to get it right. The RAP software engineers have been working hard on the algorithm and it should be nicely fined tuned. The Australian Paediatric results are still on track for a Q2 release too.

Its exciting times for RAP, and we are lucky to be part of a company that has, scalability, enormous commercial potential & and incentivised management team all in one of the hottest sectors - medtech.

Expand

green8,

Hi, I love this part of your post!

"TK was excited in relation to the USA testing with the fact all our “buckets” are now full / “overflowing” which will enable parallel submission to FDA for all the illnesses mentioned in the recent announcement, not just pneumonia."

That part is exciting and as a result, will bring forward some other milestones for FDA approval, re those other illnesses like croup, COPD, etc.

MTW

RAP Price at posting: 30.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

The business of sport: Warren Tredrea's take on this week's news

SER

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

NRX

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

The Rising Tide: How institutional adoption is shaping the future of crypto

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

RDN

Raiden gears up for exploration in final quarter of 2024

IPH

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Reporting wrap: Inghams, Accent, Mayne Pharma

There are more pages in this discussion • 25 more messages in this thread...

First 45 Last

Add RAP (ASX) to my watchlist

Ann: ResApp Presentation at ASX Spotlight Investor Conference, page-45

Top Stories

The business of sport: Warren Tredrea's take on this week's news

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

The Rising Tide: How institutional adoption is shaping the future of crypto

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

Raiden gears up for exploration in final quarter of 2024

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Reporting wrap: Inghams, Accent, Mayne Pharma

Featured News